167 related articles for article (PubMed ID: 17348492)
1. Lipid-lowering therapy--benefits and risks.
Shechter M
Isr Med Assoc J; 2007 Feb; 9(2):133; author reply 133-4. PubMed ID: 17348492
[No Abstract] [Full Text] [Related]
2. Lipid-lowering therapy--benefits and risks.
Abinader EG
Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
[No Abstract] [Full Text] [Related]
3. Intensive lipid-lowering therapy: obvious benefits, possible risks.
Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
[No Abstract] [Full Text] [Related]
4. Choice of lipid-regulating drugs.
Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632
[No Abstract] [Full Text] [Related]
5. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.
Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM
Am J Cardiol; 2008 Jun; 101(11):1606-13. PubMed ID: 18489938
[TBL] [Abstract][Full Text] [Related]
6. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
[No Abstract] [Full Text] [Related]
7. Myopathy caused by a combination rosuvastatin and fenofibrate.
Dedhia V; Munsi SC
J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
[No Abstract] [Full Text] [Related]
8. Myotoxicity associated with lipid-lowering drugs.
Baer AN; Wortmann RL
Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
[TBL] [Abstract][Full Text] [Related]
9. [Antilipemic therapy and rhabdomyolysis].
Paragh G; Balogh Z; Romics L
Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
[TBL] [Abstract][Full Text] [Related]
10. Experts confirm statins' safety but advise caution with certain patients.
Levenson D
Rep Med Guidel Outcomes Res; 2002 Jul; 13(13):1-2, 5. PubMed ID: 12515256
[No Abstract] [Full Text] [Related]
11. Worsening myopathy associated with ezetimibe in a patient with McArdle disease.
Perez-Calvo J; Civeira-Murillo F; Cabello A
QJM; 2005 Jun; 98(6):461-2. PubMed ID: 15897216
[No Abstract] [Full Text] [Related]
12. Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings.
Mosshammer D; Lorenz G; Meznaric S; Schwarz J; Muche R; Mörike K
Fam Pract; 2009 Apr; 26(2):88-95. PubMed ID: 19233960
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin--a new lipid-lowering drug.
Med Lett Drugs Ther; 2003 Oct; 45(1167):81-3. PubMed ID: 14534507
[No Abstract] [Full Text] [Related]
14. Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol?
Lee T
Harv Heart Lett; 2010 Aug; 20(12):8. PubMed ID: 20812395
[No Abstract] [Full Text] [Related]
15. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
16. [HMG-CoA reductase inhibitors in therapy of disorders of lipid metabolism].
Windler E; Greten H
Internist (Berl); 1993 Dec; 34(12):1107-14. PubMed ID: 8106206
[No Abstract] [Full Text] [Related]
17. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
[TBL] [Abstract][Full Text] [Related]
18. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
19. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Polonsky TS; Davidson MH
Am J Cardiol; 2008 Apr; 101(8A):27B-35B. PubMed ID: 18375238
[TBL] [Abstract][Full Text] [Related]
20. Fatal and widespread skeletal myopathy confirmed morphologically years after initiation of simvastatin therapy.
Boltan DD; Lachar W; Khetan A; Bouffard JP; Roberts WC
Am J Cardiol; 2007 Apr; 99(8):1171-6. PubMed ID: 17437752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
